Literature DB >> 17001000

The age incidence of chronic myeloid leukemia can be explained by a one-mutation model.

Franziska Michor1, Yoh Iwasa, Martin A Nowak.   

Abstract

Chronic myeloid leukemia (CML) is associated with the Philadelphia chromosome, which arises by a reciprocal translocation between chromosomes 9 and 22 and harbors the BCR-ABL fusion oncogene. It is unknown whether any other mutations are needed for the chronic phase of the disease. The CML incidence increases as a function of age with an exponent of approximately 3. A slope of 3 could indicate that there are two mutations, in addition to the Philadelphia translocation, that have not yet been discovered. In this work, we explore an alternative hypothesis: We study a model of cancer initiation requiring only a single mutation. A mutated cell has a net reproductive advantage over normal cells and, therefore, might give rise to clonal expansion. The cancer is detected with a probability that is proportional to the size of the mutated cell clone. This model has three waiting times: (i) the time until a mutated cell is produced, (ii) the time of clonal expansion, and (iii) the time until the clone is detected. Surprisingly, this simple process can give rise to cancer incidence curves with exponents up to 3. Therefore, the CML incidence data are consistent with the hypothesis that the Philadelphia translocation alone is sufficient to cause chronic phase CML.

Entities:  

Mesh:

Year:  2006        PMID: 17001000      PMCID: PMC1595453          DOI: 10.1073/pnas.0607006103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Chronic myeloid leukemia.

Authors:  C L Sawyers
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

3.  Acute leukaemia in bcr/abl transgenic mice.

Authors:  N Heisterkamp; G Jenster; J ten Hoeve; D Zovich; P K Pattengale; J Groffen
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

4.  Age-specific acceleration of cancer.

Authors:  Steven A Frank
Journal:  Curr Biol       Date:  2004-02-03       Impact factor: 10.834

5.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.

Authors:  C Biernaux; M Loos; A Sels; G Huez; P Stryckmans
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

6.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

Authors:  S Bose; M Deininger; J Gora-Tybor; J M Goldman; J V Melo
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

7.  bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

Authors:  A G Elefanty; I K Hariharan; S Cory
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

8.  A new theory on cancer-inducing mechanism.

Authors:  C O NORDLING
Journal:  Br J Cancer       Date:  1953-03       Impact factor: 7.640

9.  A two-stage theory of carcinogenesis in relation to the age distribution of human cancer.

Authors:  P ARMITAGE; R DOLL
Journal:  Br J Cancer       Date:  1957-06       Impact factor: 7.640

10.  The age distribution of cancer and a multi-stage theory of carcinogenesis.

Authors:  P ARMITAGE; R DOLL
Journal:  Br J Cancer       Date:  1954-03       Impact factor: 7.640

View more
  37 in total

Review 1.  Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.

Authors:  Tomas Radivoyevitch; Lynn Hlatky; Julian Landaw; Rainer K Sachs
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

2.  Population genetics meets cancer genomics.

Authors:  Roland R Regoes
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-08       Impact factor: 11.205

Review 3.  Applying the discovery of the Philadelphia chromosome.

Authors:  Daniel W Sherbenou; Brian J Druker
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Owen N Witte; Jami McLaughlin; Kenneth Dorshkind
Journal:  Blood       Date:  2007-06-06       Impact factor: 22.113

5.  Some dynamic aspects of hematopoietic stem cells.

Authors:  David Dingli; Jorge M Pacheco
Journal:  Stem Cell Rev       Date:  2008       Impact factor: 5.739

6.  Characterization and quantification of clonal heterogeneity among hematopoietic stem cells: a model-based approach.

Authors:  Ingo Roeder; Katrin Horn; Hans-Bernd Sieburg; Rebecca Cho; Christa Muller-Sieburg; Markus Loeffler
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

7.  Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.

Authors:  Tom Lenaerts; Jorge M Pacheco; Arne Traulsen; David Dingli
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

Review 8.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

9.  Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.

Authors:  Xiaomin Zheng; Claudia Oancea; Reinhard Henschler; Malcolm A S Moore; Martin Ruthardt
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

10.  Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.

Authors:  Jasmine Foo; Mark W Drummond; Bayard Clarkson; Tessa Holyoake; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2009-09-11       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.